Hepatitis B Immunization Status in Children with Chronic Kidney Disease: Experience at a Single Center, Egypt

Youssef, Doaa Mohammed; El‐Shal, Amal S.; Elbehidy, Rabab Mohamed; Fouda, Mohamed Adel; Shalaby, Sally M.; Hawy, Lamiaa Lotfy El; Elsadek, Abdelrahman Fathi; Neemat-Allah, Mayy Abd Alfattah; Ramadan, Seham M; Gohary, Amal Elsaid; Arab, Faika; Alsharkawy, Mona; Tolba, Sabry Abdel Rahman; Abdelsalam, Mohamed; Amin, Ezzat; Gehad, Mona

doi:10.3390/jcm12051864

Cited by 2 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The desired antigens can be entrapped to VLPs using genetic engineering techniques. Several VLP-based vaccines have been licensed for the prevention of infectious illnesses such as hepatitis B virus (HBV), hepatitis E virus (HEV), human papilloma virus (HPV) influenza, and hepatitis A virus due to advancements in VLP manufacturing, purification, and adjuvant optimization [156][157][158][159]. Human papilloma virus vaccine has been created using the VLP technique and licensed by the US Food and Drug Administration for clinical usage [23].…”

Section: Virus-like Particlesmentioning

confidence: 99%

Advancements in Vaccine Adjuvants: The Journey from Alum to Nano Formulations

Moni,

Abdelwahab,

Jabeen

et al. 2023

Vaccines

View full text Add to dashboard Cite

Vaccination is a groundbreaking approach in preventing and controlling infectious diseases. However, the effectiveness of vaccines can be greatly enhanced by the inclusion of adjuvants, which are substances that potentiate and modulate the immune response. This review is based on extensive searches in reputable databases such as Web of Science, PubMed, EMBASE, Scopus, and Google Scholar. The goal of this review is to provide a thorough analysis of the advances in the field of adjuvant research, to trace the evolution, and to understand the effects of the various adjuvants. Historically, alum was the pioneer in the field of adjuvants because it was the first to be approved for use in humans. It served as the foundation for subsequent research and innovation in the field. As science progressed, research shifted to identifying and exploiting the potential of newer adjuvants. One important area of interest is nano formulations. These advanced adjuvants have special properties that can be tailored to enhance the immune response to vaccines. The transition from traditional alum-based adjuvants to nano formulations is indicative of the dynamism and potential of vaccine research. Innovations in adjuvant research, particularly the development of nano formulations, are a promising step toward improving vaccine efficacy and safety. These advances have the potential to redefine the boundaries of vaccination and potentially expand the range of diseases that can be addressed with this approach. There is an optimistic view of the future in which improved vaccine formulations will contribute significantly to improving global health outcomes.

show abstract

Section: Virus-like Particlesmentioning

confidence: 99%

Advancements in Vaccine Adjuvants: The Journey from Alum to Nano Formulations

Moni,

Abdelwahab,

Jabeen

et al. 2023

Vaccines

View full text Add to dashboard Cite

show abstract

Burden of end-stage renal disease of undetermined etiology in Africa

Fiseha,

Osborne

2023

Ren Replace Ther

View full text Add to dashboard Cite

In the last two decades, there have been increasing recognition of excess cases of end-stage renal disease (ESRD) requiring renal replacement therapy without common underlying causes (diabetes, hypertension, glomerulonephritis, or any identifiable cause) in many parts of low-to-middle income countries. ESRD of unknown etiology mainly affects young working-age adults and is a global health problem with substantial morbidity, mortality and disability. In this review, we provide a comprehensive overview of the burden and outcomes of treated ESRD attributable to unknown etiology in African countries. Estimates indicate that up to 71% of adults and up to 53% children on dialysis suffer from ESRD due to unknown etiology. ESRD of unknown etiology affects mostly the economically productive young adults, males and those from rural areas. ESRD due to unknown etiology carries an almost twofold risk of mortality compared to traditional ESRD causes and account for up to 55% of the renal medical admissions burden. This review confirms that treated ESRD due to unknown etiology is a major public health issue in Africa. Future studies are urgent need for better characterizing the regional causative factors as well as for developing proactive and comprehensive approaches to prevent and treat this under-recognized disease.

show abstract

Hepatitis B Immunization Status in Children with Chronic Kidney Disease: Experience at a Single Center, Egypt

Cited by 2 publications

References 40 publications

Advancements in Vaccine Adjuvants: The Journey from Alum to Nano Formulations

Advancements in Vaccine Adjuvants: The Journey from Alum to Nano Formulations

Burden of end-stage renal disease of undetermined etiology in Africa

Contact Info

Product

Resources

About